Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.
Also called NCT07487103
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 478 participants
- Registry
-
NCT07487103
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07487103. Randomized; no masking; primary purpose treatment. Start 2026-05-01 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- QLG1091
- Intervention (Drug)
- Rybelsus
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07487103- Content hash
7552ad9c407e7cdf2db0d1f5fc862903f0cfbc0894bfdf944ae8db68dbb11640